Latest SEC filings for 10x Genomics, Inc. (TXG) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
Saxonov Serge, listed as Director, Chief Executive Officer at 10x Genomics, Inc., reported an open-market sale of 5,000 TXG shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Saxonov Serge, listed as Director, Chief Executive Officer at 10x Genomics, Inc., reported an open-market sale of 15,000 TXG shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Saxonov Serge, listed as Director, Chief Executive Officer at 10x Genomics, Inc., reported an open-market sale of 16,152 TXG shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Saxonov Serge (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Hindson Benjamin J. (Director, See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Taich Adam (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Serge Saxonov filed a Form 144 with the SEC indicating intent to sell TXG (10x Genomics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Teichmann Sarah A., listed as Director at 10x Genomics, Inc., reported an open-market sale of 7,579 TXG shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Saxonov Serge, listed as Director, Chief Executive Officer at 10x Genomics, Inc., reported an open-market sale of 9,632 TXG shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Taich Adam, listed as Chief Financial Officer at 10x Genomics, Inc., reported an open-market sale of 8,968 TXG shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Hindson Benjamin J., listed as Director, See Remarks at 10x Genomics, Inc., reported an open-market sale of 7,826 TXG shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
SARAH A POLONIUS-TEICHMANN filed a Form 144 with the SEC indicating intent to sell TXG (10x Genomics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Hindson Benjamin J. filed a Form 144 with the SEC indicating intent to sell TXG (10x Genomics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Saxonov Serge filed a Form 144 with the SEC indicating intent to sell TXG (10x Genomics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Taich Adam filed a Form 144 with the SEC indicating intent to sell TXG (10x Genomics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.